How can early cancer detection move from promise to practice? Curtiss McNair Jr., VP of Operations at PanGIA Biotech, shared his perspective on the Boombastic Health podcast.
In the interview, Curtiss explained why PanGIA Biotech is advancing a platform for true Multi-Cancer Early Detection (MCED) using urine as the biospecimen. He emphasized how co-development with oncologists ensures results that integrate directly into patient care.
For clinicians, this means diagnostic clarity. For healthcare stakeholders, it underscores PanGIA Biotech’s focus on addressing real-world challenges in oncology practice.
👉 Watch the full interview below to hear Curtiss’ perspective on bridging innovation and patient impact.
About PanGIA Biotech
PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With a steadfast commitment to research and innovation, PanGIA’s vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit www.PanGIABiotech.com.
Contacts
Joy Capps
Media@PanGIABiotech.com
843-730-3857